Intuitive Surgical Forecast, price target & analysts
Intuitive Surgical Target price 2025 - Analyst rating & recommendation
Intuitive Surgical Classifications & Recommendation:
Intuitive Surgical Price Target
| Target Price | $615.06 |
| Price | $547.78 |
| Potential | 12.28% |
| Number of Estimates | 32 |
| 32 Analysts have issued a price target Intuitive Surgical 2026 . The average Intuitive Surgical target price is $615.06. This is 12.28% higher than the current stock price. The highest price target is $735.00 34.18% , the lowest is $444.40 18.87% . | |
| A rating was issued by 41 analysts: 27 Analysts recommend Intuitive Surgical to buy, 13 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Intuitive Surgical stock has an average upside potential 2026 of 12.28% . Most analysts recommend the Intuitive Surgical stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2032
38 Analysts have issued a sales forecast Intuitive Surgical 2025 . The average Intuitive Surgical sales estimate is $10.1b . This is 5.12% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $10.6b 10.16% , the lowest is $9.5b 0.91% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | $8.4b | 17.24% |
|---|---|---|
| 2025 | $10.1b | 20.98% |
| 2026 | $11.6b | 15.11% |
| 2027 | $13.2b | 13.46% |
| 2028 | $14.2b | 7.81% |
| 2029 | $16.7b | 17.32% |
| 2030 | $19.5b | 16.91% |
| 2031 | $20.4b | 4.30% |
| 2032 | $22.6b | 11.14% |
29 Analysts have issued an Intuitive Surgical EBITDA forecast 2025. The average Intuitive Surgical EBITDA estimate is $4.1b . This is 20.52% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $4.6b 32.83% , the lowest is $3.8b 10.68% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $2.4b | 32.27% |
|---|---|---|
| 2025 | $4.1b | 75.49% |
| 2026 | $4.7b | 13.43% |
| 2027 | $5.6b | 19.06% |
| 2028 | $6.0b | 8.05% |
| 2029 | $7.4b | 22.84% |
| 2030 | $9.2b | 24.23% |
EBITDA Margin
| 2024 | 28.25% | 12.82% |
|---|---|---|
| 2025 | 40.97% | 45.05% |
| 2026 | 40.37% | 1.46% |
| 2027 | 42.37% | 4.95% |
| 2028 | 42.46% | 0.21% |
| 2029 | 44.46% | 4.71% |
| 2030 | 47.24% | 6.25% |
38 Intuitive Surgical Analysts have issued a net profit forecast 2025. The average Intuitive Surgical net profit estimate is $3.2b . This is 14.72% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $3.3b 19.90% , the lowest is $2.9b 4.11% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | $2.3b | 29.18% |
|---|---|---|
| 2025 | $3.2b | 35.68% |
| 2026 | $3.5b | 12.53% |
| 2027 | $4.1b | 15.20% |
| 2028 | $4.4b | 7.45% |
| 2029 | $5.2b | 17.94% |
| 2030 | $6.5b | 25.21% |
Net Margin
| 2024 | 27.81% | 10.18% |
|---|---|---|
| 2025 | 31.19% | 12.16% |
| 2026 | 30.49% | 2.24% |
| 2027 | 30.96% | 1.54% |
| 2028 | 30.85% | 0.36% |
| 2029 | 31.02% | 0.55% |
| 2030 | 33.22% | 7.09% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
38 Analysts have issued a Intuitive Surgical forecast for earnings per share. The average Intuitive Surgical EPS is $8.79 . This is 15.81% higher than earnings per share in the financial year 2024. The highest EPS forecast is $9.19 21.08% , the lowest is $7.98 5.14% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $6.42 | 27.63% |
|---|---|---|
| 2025 | $8.79 | 36.92% |
| 2026 | $9.89 | 12.51% |
| 2027 | $11.40 | 15.27% |
| 2028 | $12.25 | 7.46% |
| 2029 | $14.44 | 17.88% |
| 2030 | $18.08 | 25.21% |
| 2031 | $18.07 | 0.06% |
| 2032 | $19.59 | 8.41% |
P/E ratio
| Current | 72.17 | 11.91% |
|---|---|---|
| 2025 | 62.31 | 13.66% |
| 2026 | 55.37 | 11.14% |
| 2027 | 48.07 | 13.18% |
| 2028 | 44.73 | 6.95% |
| 2029 | 37.93 | 15.20% |
| 2030 | 30.29 | 20.14% |
Based on analysts' sales estimates for 2025, the Intuitive Surgical stock is valued at an EV/Sales of 18.38 and an P/S ratio of 19.22 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 19.33 | 13.59% |
|---|---|---|
| 2025 | 18.38 | 4.89% |
| 2026 | 15.97 | 13.13% |
| 2027 | 14.08 | 11.87% |
| 2028 | 13.06 | 7.25% |
| 2029 | 11.13 | 14.76% |
| 2030 | 9.52 | 14.47% |
| 2031 | 9.13 | 4.13% |
| 2032 | 8.21 | 10.02% |
P/S ratio
| Current | 20.20 | 11.88% |
|---|---|---|
| 2025 | 19.22 | 4.87% |
| 2026 | 16.70 | 13.13% |
| 2027 | 14.71 | 11.87% |
| 2028 | 13.65 | 7.25% |
| 2029 | 11.63 | 14.76% |
| 2030 | 9.95 | 14.47% |
| 2031 | 9.54 | 4.13% |
| 2032 | 8.58 | 10.02% |
Intuitive Surgical...
Current Intuitive Surgical Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| UBS |
Neutral
➜
Neutral
|
Unchanged | Oct 23 2025 |
| Wells Fargo |
Overweight
➜
Overweight
|
Unchanged | Oct 22 2025 |
| Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | Oct 22 2025 |
| Raymond James |
Outperform
➜
Outperform
|
Unchanged | Oct 22 2025 |
| RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Oct 22 2025 |
| Truist Securities |
Buy
➜
Buy
|
Unchanged | Oct 22 2025 |
| BTIG |
Buy
➜
Buy
|
Unchanged | Oct 22 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
UBS:
Neutral
➜
Neutral
|
Oct 23 2025 |
|
Unchanged
Wells Fargo:
Overweight
➜
Overweight
|
Oct 22 2025 |
|
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
Oct 22 2025 |
|
Unchanged
Raymond James:
Outperform
➜
Outperform
|
Oct 22 2025 |
|
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Oct 22 2025 |
|
Unchanged
Truist Securities:
Buy
➜
Buy
|
Oct 22 2025 |
|
Unchanged
BTIG:
Buy
➜
Buy
|
Oct 22 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
